Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News ARCA Biopharma Inc ABIO

Healthcare Biotechnology
ARCA biopharma, Inc. is a clinical-stage biopharmaceutical company engaged in developing genetically and other targeted therapies for cardiovascular diseases through a precision medicine approach to drug development. The Company's lead product candidate is Gencaro (bucindolol hydrochloride) for the treatment of atrial fibrillation (AF) in patients with chronic heart failure (HF). Gencaro is... see more

Recent & Breaking News (NDAQ:ABIO)

ARCA biopharma Retains Ladenburg Thalmann to Support Strategic Options Review

GlobeNewswire May 5, 2022

ARCA biopharma Announces First Quarter 2022 Financial Results

GlobeNewswire May 2, 2022

ARCA biopharma Establishes Special Committee of the Board of Directors

GlobeNewswire April 18, 2022

ARCA biopharma Reports Topline Results for ASPEN-COVID-19 Phase 2b Clinical Trial

GlobeNewswire March 31, 2022

ARCA biopharma Announces 2021 Financial Results and Provides Corporate Update

GlobeNewswire March 14, 2022

Data on Gencaro Impact on Prevention of Bradycardia Published in Heart Rhythm O2

GlobeNewswire January 4, 2022

ARCA biopharma Announces Completion of Enrollment in Phase 2b ASPEN-COVID-19 Clinical Trial Evaluating rNAPc2 as a Potential Treatment for Patients Hospitalized with COVID-19

GlobeNewswire December 2, 2021

ARCA biopharma to Present at the Q4 Virtual Investor Summit on November 17th

GlobeNewswire November 9, 2021

ARCA biopharma Announces Third Quarter 2021 Financial Results and Provides Corporate Update

GlobeNewswire November 2, 2021

ASPEN-COVID-19 Data and Safety Monitoring Committee Recommends Continuing Phase 2b Clinical Trial to Completion Based on Interim Analysis of Efficacy and Safety Data

GlobeNewswire October 28, 2021

ARCA biopharma Announces Enrollment of First International Patient in Phase 2b Clinical Trial Evaluating rNAPc2 as a Potential Treatment for COVID-19

GlobeNewswire September 16, 2021

ARCA biopharma to Present at the Q3 Virtual Investor Summit on August 18th

GlobeNewswire August 16, 2021

ARCA biopharma Announces Submission of PCT Patent Application for the Treatment of Coronavirus Infection and Associated Coagulopathy with rNAPc2

GlobeNewswire August 9, 2021

ARCA biopharma Announces Second Quarter 2021 Financial Results and Provides Corporate Update

GlobeNewswire August 4, 2021

Gencaro Atrial Fibrillation Phase 2B Results Selected for Publication in Circulation: Arrhythmia and Electrophysiology

GlobeNewswire July 28, 2021

ARCA biopharma Provides Update on ASPEN-COVID-19 Phase 2b Clinical Trial Evaluating rNAPc2 as a Potential Treatment for COVID-19

GlobeNewswire July 13, 2021

ARCA biopharma to Present at Access to Giving Virtual Investor Conference on July 13th

GlobeNewswire July 9, 2021

50+ Companies to Present at the Access to Giving Virtual Investor Conference on July 13th - 15th, 2021

Accesswire July 8, 2021

ARCA biopharma Announces rNAPc2 COVID-19 Patent Assignment Agreement

GlobeNewswire July 7, 2021

50+ Companies to Present at the Access to Giving Virtual Investor Conference on July 13th - 15th, 2021

Accesswire June 23, 2021